IONS

SEC source: 0000874015-25-000162 · edgardoc.xml · nonDerivative · entry 1

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000161 · edgardoc.xml · derivative · entry 2

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,080

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000161 · edgardoc.xml · nonDerivative · entry 1

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000160 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,141

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000160 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 136,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000159 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,220

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000159 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000158 · edgardoc.xml · derivative · entry 2

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,220

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000158 · edgardoc.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,086

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000157 · edgardoc.xml · derivative · entry 3

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,897

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000157 · edgardoc.xml · nonDerivative · entry 1

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,298

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000155 · edgardoc.xml · derivative · entry 3

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,220

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000155 · edgardoc.xml · nonDerivative · entry 1

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000156 · edgardoc.xml · derivative · entry 2

Diaz Allene M. · CIK 0001773314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,220

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000156 · edgardoc.xml · nonDerivative · entry 1

Diaz Allene M. · CIK 0001773314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000146 · edgardoc.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,820

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $41.79 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000144 · edgardoc.xml · derivative · entry 2

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,159

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000144 · edgardoc.xml · derivative · entry 1

YANG MICHAEL J. · CIK 0001702283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000143 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000143 · edgardoc.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000142 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000142 · edgardoc.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000141 · edgardoc.xml · derivative · entry 2

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000141 · edgardoc.xml · derivative · entry 1

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000139 · edgardoc.xml · derivative · entry 2

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000139 · edgardoc.xml · derivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000140 · edgardoc.xml · derivative · entry 2

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,976

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000140 · edgardoc.xml · derivative · entry 1

KLEIN JOSEPH III · CIK 0001206369 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000138 · edgardoc.xml · derivative · entry 2

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,976

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000138 · edgardoc.xml · derivative · entry 1

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000137 · edgardoc.xml · derivative · entry 2

Diaz Allene M. · CIK 0001773314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000137 · edgardoc.xml · derivative · entry 1

Diaz Allene M. · CIK 0001773314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000136 · edgardoc.xml · derivative · entry 2

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000136 · edgardoc.xml · derivative · entry 1

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000125 · edgardoc.xml · nonDerivative · entry 1

Hayden Michael R · CIK 0001352908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,219

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $31.50 to $32.09 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) on this Form 4.

SEC source: 0000874015-25-000120 · edgardoc.xml · nonDerivative · entry 2

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,660

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-25-000119 · edgardoc.xml · nonDerivative · entry 2

Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,199

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.35 to $28.37 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000118 · edgardoc.xml · nonDerivative · entry 2

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,926

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.37 to $28.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000120 · edgardoc.xml · derivative · entry 3

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,215

Underlying: Common Stock · 1,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000120 · edgardoc.xml · nonDerivative · entry 1

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000119 · edgardoc.xml · derivative · entry 3

Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,677

Underlying: Common Stock · 12,226 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000119 · edgardoc.xml · nonDerivative · entry 1

Jenne Kyle · CIK 0001791857 · EVP, Chf GL Pdt Str Ofcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000118 · edgardoc.xml · derivative · entry 4

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,511

Underlying: Common Stock · 10,837 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000118 · edgardoc.xml · nonDerivative · entry 1

Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000105 · edgardoc.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,980

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.

SEC source: 0000874015-25-000103 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,432

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.

SEC source: 0000874015-25-000102 · edgardoc.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,799

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.

SEC source: 0000874015-25-000101 · edgardoc.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,120

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.

SEC source: 0000874015-25-000100 · edgardoc.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,492

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.

SEC source: 0000874015-25-000099 · edgardoc.xml · nonDerivative · entry 1

Birchler Brian · CIK 0001970151 · EVP, Corp and Development Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,465

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.